What is Chardan Capital’s Forecast for CRSP FY2025 Earnings?

CRISPR Therapeutics AG (NASDAQ:CRSP) – Research analysts at Chardan Capital raised their FY2025 earnings estimates for CRISPR Therapeutics in a report released on Wednesday, May 7th. Chardan Capital analyst Y. Livshits now anticipates that the company will post earnings of ($4.60) per share for the year, up from their previous forecast of ($4.62). Chardan Capital has a “Buy” rating and a $82.00 price target on the stock. The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.16) per share.

Several other research analysts also recently issued reports on CRSP. Stifel Nicolaus dropped their target price on shares of CRISPR Therapeutics from $53.00 to $49.00 and set a “hold” rating on the stock in a research note on Thursday, February 13th. Needham & Company LLC reduced their target price on shares of CRISPR Therapeutics from $84.00 to $81.00 and set a “buy” rating for the company in a report on Wednesday, May 7th. TD Cowen raised shares of CRISPR Therapeutics from a “sell” rating to a “hold” rating and set a $35.00 target price for the company in a report on Wednesday, February 12th. Royal Bank of Canada reduced their target price on shares of CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating for the company in a report on Wednesday, February 12th. Finally, Cantor Fitzgerald reiterated a “neutral” rating on shares of CRISPR Therapeutics in a research report on Wednesday, February 19th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $71.75.

CRISPR Therapeutics Stock Performance

Shares of NASDAQ CRSP opened at $37.59 on Monday. The firm’s 50 day moving average price is $38.03 and its 200-day moving average price is $42.64. The company has a market cap of $3.25 billion, a PE ratio of -8.60 and a beta of 1.88. CRISPR Therapeutics has a 52-week low of $30.04 and a 52-week high of $67.88.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Tuesday, May 6th. The company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. CRISPR Therapeutics’s revenue was up 71.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.43) EPS.

Insider Buying and Selling

In other CRISPR Therapeutics news, Director John Greene acquired 7,000 shares of the stock in a transaction on Wednesday, February 26th. The stock was acquired at an average price of $44.85 per share, for a total transaction of $313,950.00. Following the completion of the transaction, the director now directly owns 7,000 shares of the company’s stock, valued at $313,950. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Samarth Kulkarni sold 9,973 shares of the stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total transaction of $423,054.66. Following the transaction, the chief executive officer now owns 180,890 shares of the company’s stock, valued at $7,673,353.80. This trade represents a 5.23% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 32,381 shares of company stock worth $1,608,243. 4.30% of the stock is owned by insiders.

Institutional Investors Weigh In On CRISPR Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in CRSP. Intellectus Partners LLC lifted its stake in shares of CRISPR Therapeutics by 3.6% in the 4th quarter. Intellectus Partners LLC now owns 7,131 shares of the company’s stock valued at $281,000 after purchasing an additional 250 shares during the period. Farrow Financial Inc. raised its position in CRISPR Therapeutics by 1.4% during the fourth quarter. Farrow Financial Inc. now owns 20,097 shares of the company’s stock worth $777,000 after acquiring an additional 270 shares during the period. Kestra Private Wealth Services LLC grew its holdings in shares of CRISPR Therapeutics by 1.5% during the fourth quarter. Kestra Private Wealth Services LLC now owns 20,636 shares of the company’s stock worth $812,000 after buying an additional 310 shares in the last quarter. SFE Investment Counsel grew its holdings in shares of CRISPR Therapeutics by 5.8% during the first quarter. SFE Investment Counsel now owns 6,507 shares of the company’s stock worth $221,000 after buying an additional 355 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in shares of CRISPR Therapeutics by 7.6% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 5,252 shares of the company’s stock worth $215,000 after buying an additional 372 shares in the last quarter. Hedge funds and other institutional investors own 69.20% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.